David E Connor1, Ganta V Chaitanya2, Prashant Chittiboina3, Paul McCarthy4, L Keith Scott5, Lisa Schrott6, Alireza Minagar7, Anil Nanda8, J Steven Alexander9. 1. Baptist Health Neurosurgery Arkansas, Little Rock, AR, United States. Electronic address: dconnor1979@gmail.com. 2. Cardiovascular Research Center, University of Virginia, Charlottesville, VA, United States. Electronic address: vg6u@virginia.edu. 3. Surgical Neurology Branch, National Institute of Neurological Diseases and Stroke, Bethesda, MD, United States. Electronic address: prashant.chittiboina@nih.gov. 4. Department of Medicine, Sect. of Nephrology, University of Maryland, Baltimore, MD, United States. Electronic address: pbluesmd@yahoo.com. 5. Department of Critical Care Medicine, Louisiana State University Health Sciences Center-Shreveport, LA, United States. Electronic address: lscott2@lsuhsc.edu. 6. Department of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center-Shreveport, LA, United States. Electronic address: lisaschrottl@gmail.com. 7. Department of Neurology, Louisiana State University Health Sciences Center-Shreveport, LA, United States. Electronic address: aminag@lsuhsc.edu. 8. Department of Neurosurgery, Louisiana State University Health Sciences Center-Shreveport, LA, United States. Electronic address: ananda@lsuhsc.edu. 9. Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center-Shreveport, LA, United States. Electronic address: jalexa@lsuhsc.edu.
Abstract
BACKGROUND: Proteomic analysis of cerebrospinal fluid (CSF) has shown great promise in identifying potential markers of injury in neurodegenerative diseases [1-13]. Here we compared CSF proteomes in healthy individuals, with patients diagnosed with traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) in order to characterize molecular biomarkers which might identify these different clinical states and describe different molecular mechanisms active in each disease state. METHODS: Patients presenting to the Neurosurgery service at the Louisiana State University Hospital-Shreveport with an admitting diagnosis of TBI or SAH were prospectively enrolled. Patients undergoing CSF sampling for diagnostic procedures were also enrolled as controls. CSF aliquots were subjected to 2-dimensional gel electrophoresis (2D GE) and spot percentage densities analyzed. Increased or decreased spot expression (compared to controls) was defined in terms of in spot percentages, with spots showing consistent expression change across TBI or SAH specimens being followed up by Matrix-Assisted Laser Desorption/Ionization mass spectrometry (MALDI-MS). Polypeptide masses generated were matched to known standards using a search of the NCBI and/or GenPept databases for protein matches. Eight hundred fifteen separately identifiable polypeptide migration spots were identified on 2D GE gels. MALDI-MS successfully identified 13 of 22 selected 2D GE spots as recognizable polypeptides. RESULTS: Statistically significant changes were noted in the expression of fibrinogen, carbonic anhydrase-I (CA-I), peroxiredoxin-2 (Prx-2), both α and β chains of hemoglobin, serotransferrin (Tf) and N-terminal haptoglobin (Hp) in TBI and SAH specimens, as compared to controls. The greatest mean fold change among all specimens was seen in CA-I and Hp at 30.7 and -25.7, respectively. TBI specimens trended toward greater mean increases in CA-I and Prx-2 and greater mean decreases in Hp and Tf. CONCLUSIONS: Consistent CSF elevation of CA-I and Prx-2 with concurrent depletion of Hp and Tf may represent a useful combination of biomarkers for the prediction of severity and prognosis following brain injury.
BACKGROUND: Proteomic analysis of cerebrospinal fluid (CSF) has shown great promise in identifying potential markers of injury in neurodegenerative diseases [1-13]. Here we compared CSF proteomes in healthy individuals, with patients diagnosed with traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) in order to characterize molecular biomarkers which might identify these different clinical states and describe different molecular mechanisms active in each disease state. METHODS:Patients presenting to the Neurosurgery service at the Louisiana State University Hospital-Shreveport with an admitting diagnosis of TBI or SAH were prospectively enrolled. Patients undergoing CSF sampling for diagnostic procedures were also enrolled as controls. CSF aliquots were subjected to 2-dimensional gel electrophoresis (2D GE) and spot percentage densities analyzed. Increased or decreased spot expression (compared to controls) was defined in terms of in spot percentages, with spots showing consistent expression change across TBI or SAH specimens being followed up by Matrix-Assisted Laser Desorption/Ionization mass spectrometry (MALDI-MS). Polypeptide masses generated were matched to known standards using a search of the NCBI and/or GenPept databases for protein matches. Eight hundred fifteen separately identifiable polypeptide migration spots were identified on 2D GE gels. MALDI-MS successfully identified 13 of 22 selected 2D GE spots as recognizable polypeptides. RESULTS: Statistically significant changes were noted in the expression of fibrinogen, carbonic anhydrase-I (CA-I), peroxiredoxin-2 (Prx-2), both α and β chains of hemoglobin, serotransferrin (Tf) and N-terminal haptoglobin (Hp) in TBI and SAH specimens, as compared to controls. The greatest mean fold change among all specimens was seen in CA-I and Hp at 30.7 and -25.7, respectively. TBI specimens trended toward greater mean increases in CA-I and Prx-2 and greater mean decreases in Hp and Tf. CONCLUSIONS:Consistent CSF elevation of CA-I and Prx-2 with concurrent depletion of Hp and Tf may represent a useful combination of biomarkers for the prediction of severity and prognosis following brain injury.
Authors: Christian Schachtrup; Jae K Ryu; Matthew J Helmrick; Eirini Vagena; Dennis K Galanakis; Jay L Degen; Richard U Margolis; Katerina Akassoglou Journal: J Neurosci Date: 2010-04-28 Impact factor: 6.167
Authors: C M McDonald; K M Jaffe; G C Fay; N L Polissar; K M Martin; S Liao; J B Rivara Journal: Arch Phys Med Rehabil Date: 1994-03 Impact factor: 3.966
Authors: Sang Min Jung; Kibeom Lee; Joung Wook Lee; Hong Namkoong; Hyun Kee Kim; Sanghee Kim; Hae Ri Na; Seon-Ah Ha; Jae-Ryong Kim; Jesang Ko; Jin Woo Kim Journal: Neurosci Lett Date: 2008-03-18 Impact factor: 3.046
Authors: Mario Ganau; Nikolaos Syrmos; Marco Paris; Laura Ganau; Gianfranco K I Ligarotti; Ali Moghaddamjou; Salvatore Chibbaro; Andrea Soddu; Rossano Ambu; Lara Prisco Journal: Medicines (Basel) Date: 2018-02-05
Authors: Elisa Pin; David Just; Caroline Lindblad; Faiez Al Nimer; Peter Nilsson; Bo-Michael Bellander; Mikael Svensson; Fredrik Piehl; Eric Peter Thelin Journal: Crit Care Date: 2021-03-12 Impact factor: 9.097